Literature DB >> 30167842

TIMP-1 Promotes the Immune Response in Influenza-Induced Acute Lung Injury.

Jenieke R Allen1, Lingyin Ge1, Ying Huang1, Rena Brauer1, Tanyalak Parimon1, Suzanne L Cassel1, Fayyaz S Sutterwala1, Peter Chen2.   

Abstract

INTRODUCTION: Influenza infects millions of people each year causing respiratory distress and death in severe cases. On average, 200,000 people annually are hospitalized in the United States for influenza related complications. Tissue inhibitor of metalloproteinase-1 (TIMP-1), a secreted protein that inhibits MMPs, has been found to be involved in lung inflammation. Here, we evaluated the role of TIMP-1 in the host response to influenza-induced lung injury.
METHODS: Wild-type (WT) and Timp1-deficient (Timp1-/-) mice that were 8-12 weeks old were administered A/PR/8/34 (PR8), a murine adapted H1N1 influenza virus, and euthanized 6 days after influenza installation. Bronchoalveolar lavage fluid and lungs were harvested from each mouse for ELISA, protein assay, PCR, and histological analysis. Cytospins were executed on bronchoalveolar lavage fluid to identify immune cells based on morphology and cell count.
RESULTS: WT mice experienced significantly more weight loss compared to Timp1-/- mice after influenza infection. WT mice demonstrated more immune cell infiltrate and airway inflammation. Interestingly, PR8 levels were identical between the WT and Timp1-/- mice 6 days post-influenza infection.
CONCLUSION: The data suggest that Timp1 promotes the immune response in the lungs after influenza infection facilitating an injurious phenotype as a result of influenza infection.

Entities:  

Keywords:  Acute lung injury; Influenza; PR8; Timp1

Mesh:

Substances:

Year:  2018        PMID: 30167842      PMCID: PMC6283619          DOI: 10.1007/s00408-018-0154-2

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  27 in total

1.  Selective induction of tissue inhibitor of metalloproteinase-1 in bleomycin-induced pulmonary fibrosis.

Authors:  D K Madtes; A L Elston; L A Kaback; J G Clark
Journal:  Am J Respir Cell Mol Biol       Date:  2001-05       Impact factor: 6.914

2.  Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein.

Authors:  Ki-Kyung Jung; Xu-Wen Liu; Rosemarie Chirco; Rafael Fridman; Hyeong-Reh Choi Kim
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

3.  Multicohort analysis reveals baseline transcriptional predictors of influenza vaccination responses.

Authors: 
Journal:  Sci Immunol       Date:  2017-08-25

4.  Influenza virus propagation in embryonated chicken eggs.

Authors:  Rena Brauer; Peter Chen
Journal:  J Vis Exp       Date:  2015-03-19       Impact factor: 1.355

Review 5.  Engineering of selective TIMPs.

Authors:  H Nagase; Q Meng; V Malinovskii; W Huang; L Chung; W Bode; K Maskos; K Brew
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

6.  Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling.

Authors:  Virginia Egea; Stefan Zahler; Nicole Rieth; Peter Neth; Tanja Popp; Kai Kehe; Marianne Jochum; Christian Ries
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-05       Impact factor: 11.205

7.  Upstream tissue inhibitor of metalloproteinases-1 (TIMP-1) element-1, a novel and essential regulatory DNA motif in the human TIMP-1 gene promoter, directly interacts with a 30-kDa nuclear protein.

Authors:  J E Trim; S K Samra; M J Arthur; M C Wright; M McAulay; R Beri; D A Mann
Journal:  J Biol Chem       Date:  2000-03-03       Impact factor: 5.157

8.  Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study.

Authors:  Sidse Ørnbjerg Würtz; Susanne Møller; Henning Mouridsen; Pernille Briaemer Hertel; Esbern Friis; Nils Brünner
Journal:  Mol Cell Proteomics       Date:  2007-11-12       Impact factor: 5.911

Review 9.  The pathology of influenza virus infections.

Authors:  Jeffery K Taubenberger; David M Morens
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

10.  Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1.

Authors:  Stephen J Crocker; Ricardo F Frausto; Jason K Whitmire; Nicola Benning; Richard Milner; J Lindsay Whitton
Journal:  Am J Pathol       Date:  2007-11-30       Impact factor: 4.307

View more
  5 in total

1.  Remifentanil ameliorates lung injury in neonate rats with acute respiratory distress by down-regulating TIMP1 expression.

Authors:  Xing Wu; Lili Guo; Guomei Ye
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

2.  Early Amplified Respiratory Bioactive Lipid Response Is Associated With Worse Outcomes in Pediatric Influenza-Related Respiratory Failure.

Authors:  Veronica G Anania; Adrienne G Randolph; Xiaoying Yang; Allen Nguyen; Margaret M Newhams; W Rodney Mathews; Carrie M Rosenberger; Jacqueline M McBride
Journal:  Open Forum Infect Dis       Date:  2020-04-09       Impact factor: 3.835

3.  Evidence of a dysregulated vitamin D endocrine system in SARS-CoV-2 infected patient's lung cells.

Authors:  Bijesh George; Revikumar Amjesh; Aswathy Mary Paul; T R Santhoshkumar; Madhavan Radhakrishna Pillai; Rakesh Kumar
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379

4.  Understanding Gene Expression and Transcriptome Profiling of COVID-19: An Initiative Towards the Mapping of Protective Immunity Genes Against SARS-CoV-2 Infection.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Hatem Zayed; Sang-Soo Lee
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

5.  Notoginsenoside R1 Facilitated Wound Healing in High-Fat Diet/Streptozotocin-Induced Diabetic Rats.

Authors:  Guangzhao Cao; Changpei Xiang; Rui Zhou; Yi Zhang; He Xu; Hongjun Yang; Jingjing Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-01-13       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.